We and others [3, 4, 14–17] have shown that by increasing the concentration of glucose in the urinary filtrate, SGLT2-inhibitors safely lower 1,5-AG in blood and as a result are now becoming widely used in the clinic to treat these patients’ neutropenia. The gene discussed is SLC5A2; the disease is Decreased total neutrophil count.